CBIZ Reports Third-Quarter and Nine Months Ended September 30, 2026 Financial Results

CBIZ reported Q3 2026 revenue of $702M, up 1.2%, and net income of $47M, up 56.7%; adjusted EBITDA rose 6.3% to $132M and adjusted diluted EPS increased 14.2% to $1.21. For the first nine months, revenue grew 0.8% to $2.233B, while adjusted EBITDA declined 1.2% to $479M. CBIZ also reiterated the proposed all-cash acquisition by Grant Thornton, backed by New Mountain Capital, at an enterprise value of $5.0B, or $55 per share.

Analysis

CBZ’s operating update is secondary to the fixed $55 cash consideration: absent a competing bid or revised terms, improving quarterly adjusted EBITDA does not create much standalone equity upside, while weaker nine-month EBITDA cautions against assuming the business is accelerating. The key market variable is therefore deal completion probability and timing, not the headline EPS growth. The mismatch between stronger GAAP EPS and softer nine-month adjusted EBITDA warrants checking the reconciliation before treating earnings quality as improving.

Near term, the results may modestly support the buyer’s view of the business, but they do not independently resolve closing, financing, or regulatory risks. Over 1–3 months, monitor transaction filings, required approvals, financing disclosures, and any change in closing timetable. A failed or delayed transaction would expose CBZ to a standalone valuation reset; the downside cannot be responsibly quantified without its unaffected price and valuation context. Over 6–18 months, combining CBIZ with Grant Thornton could intensify competition for professional-services talent and clients, potentially pressuring rivals such as RSM and BDO, though integration and retention outcomes remain unverified. The contrarian point: strong reported GAAP EPS growth may attract attention, but the cash offer likely caps the stock; deal spread and break risk should dominate positioning.

Key Decisions for Investors

• Treat CBZ as a merger-arbitrage situation, not an earnings-growth long. Before entering, compare the live share price with $55 and calculate the annualized gross spread using a realistic close date; no price or timeline is supplied here, so there is no unconditional entry recommendation.
• For an existing CBZ position, consider trimming exposure above the level justified by the remaining deal spread rather than extrapolating GAAP EPS growth. Reassess if the buyer revises terms or a credible competing proposal emerges.
• Track transaction approvals, financing certainty, and closing-timetable updates as the primary 1–3 month catalysts. A material delay, adverse approval development, or termination would falsify the completion thesis and raise break risk.
• Verify adjusted EBITDA reconciliation, cash-flow composition, and segment trends in the full release. If underlying operating performance weakens, it could reduce deal confidence; if cash generation and EBITDA prove durable, it may modestly cushion standalone downside but does not remove the $55 cap.